
Jenburkt Pharma Re-appoints Dilip H. Bhuta as Whole Time Director & CFO for 5 Years
Jenburkt Pharmaceuticals Ltd announced the re-appointment of Shri. Dilip H. Bhuta as Whole Time Director and Chief Financial Officer (CFO) for a term of five years, effective April 1, 2027, to March 31, 2032. The shareholders approved this re-appointment at the 41st Annual General Meeting (AGM). The company also secured approval for remuneration payment for a three-year period from April 1, 2027, to March 31, 2030. Shri. Bhuta, aged 74, has been with the company since 2013 and brings extensive banking experience.
Key Highlights
- Shri. Dilip H. Bhuta re-appointed as Whole Time Director & CFO.
- New tenure: April 1, 2027, to March 31, 2032 (5 years).
- Remuneration approved for April 1, 2027, to March 31, 2030 (3 years).
- Shareholder approval received at the 41st AGM.
- Bhuta has been with the company since July 16, 2013.
Price Impact
More from JENBURPH
Jenburkt Pharma: Counter Cyclical Investment Buys 4,608 Shares
Jenburkt Pharmaceuticals Declares Standalone Unaudited Q2 FY27 Results
Jenburkt Q2 FY27: PAT flat YoY at ₹10.2 Cr as margins compress despite 6% revenue growth